| ALCON, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110190381 | RNAI-MEDIATED INHIBITION OF FRIZZLED RELATED PROTEIN-1 FOR TREATMENT OF GLAUCOMA - RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma. | 08-04-2011 |
| 20110190203 | Ophthalmic Compositions Containing A Synergistic Combination Of Two Polymers - Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity. | 08-04-2011 |
| 20110178202 | VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS - Azo compounds that block visible light are disclosed. These light absorbers are particularly suitable for use in intraocular lens materials. | 07-21-2011 |
| 20110160210 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS - An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient. | 06-30-2011 |
| 20110144127 | AGENTS FOR TREATMENT OF GLAUCOMATOUS RETINOPATHY AND OPTIC NEUROPATHY - Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating glaucomatous retinopathy or optic neuropathy. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof. | 06-16-2011 |
| 20110130451 | METHOD OF TREATING DRY EYE DISORDERS AND UVEITIS - The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis. | 06-02-2011 |
| 20110124708 | RNAI-MEDIATED INHIBITION OF OCULAR HYPERTENSION TARGETS - RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na | 05-26-2011 |
| 20110106096 | Monitoring Thermal Conditions To Vary Operation of an Ultrasonic Needle Tip of a Surgical Instrument - A method and apparatus to operate a surgical instrument in response to a thermal condition being detected that warrants curtailment of further operation. When the thermal condition is reached, command signals are generated that cause a needle of the surgical instrument to either have its vibrational speed slowed, have its vibrational movement stopped, or have it withdrawn from its relative position. The detection is of infrared radiation wavelengths and is carried out with either a thermal imaging device of a thermal recognition device. A corresponding temperature of the detected infrared radiation wavelengths is compared to a critical temperature to determine whether the thermal condition has been reached. | 05-05-2011 |
| 20110105765 | UV-ABSORBERS FOR OPHTHALMIC LENS MATERIALS - 1,4-disubstituted-1,2,3-triazole UV absorbing monomers are disclosed. The UV absorbers are particularly suitable for use in intraocular lens materials. | 05-05-2011 |
| 20110105453 | Superoxide Dismutase Mimics For The Treatment Of Optic Nerve And Retinal Damage - Methods for preventing and treating damage to the optic nerve and/or retina by the use of SOD mimics, particularly pentaazacycle Mn | 05-05-2011 |
| 20110098314 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA - The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient. | 04-28-2011 |
| 20110082200 | 5,6,7-TRIHYDROXYHEPTANOIC ACID AND ANALOGS FOR THE TREATMENT OF OCULAR DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVE AND ANGIOGENIC RESPONSES - Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed. | 04-07-2011 |
| 20110054008 | RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma - RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression. | 03-03-2011 |
| 20110046259 | UV-ABSORBERS FOR OPHTHALMIC LENS MATERIALS - UV absorbing monomers that are particularly useful in ophthalmic devices are disclosed. | 02-24-2011 |
| 20110046258 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS - Disclosed are soft, high refractive index, acrylic device materials. The materials contain a copolymeric additive for glistening resistance. | 02-24-2011 |
| 20110028534 | RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERS - RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention. | 02-03-2011 |
| 20110015563 | Method Of Controlling A Surgical System Based On A Rate Of Change Of An Operating Parameter - A surgical system that is able to sense the onset of an occlusion or other surgical event as well as when an occlusion breaks. To help avoid overheating of the tip, the system of the present invention predicts the temperature of the eye using irrigation flow rate and reduces the power to the handpiece automatically if an overheating situation is predicted. Alternatively or in addition, the system of the present invention monitors the power drawn by the handpiece, which is indicative of the cutting load on the tip, and automatically adjusts the power or stroke of the tip to compensate for increased loads on the tip. | 01-20-2011 |
| 20110015271 | TOPICAL NEPAFENAC FORMULATIONS - Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration. | 01-20-2011 |
| 20110015151 | COMBINATION OF VISCOELASTICS FOR USE DURING SURGERY - An improved viscoelastic composition useful in the performance of ophthalmic surgical procedures and especially cataract procedures is disclosed. The embodiments of the composition comprise combinations of sodium hyaluronate and chondroitin sulfate and exhibit an improved rheological profile. | 01-20-2011 |
| 20110004301 | UV/VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS - Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials. | 01-06-2011 |
| 20110003910 | VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS - Azo compounds that block visible light are disclosed. These light absorbers are particularly suitable for use in intraocular lens materials. | 01-06-2011 |
| 20100331764 | Controlling A Phacoemulsification Surgical System By Transitioning Between Pulse and Burst Modes - Methods of manipulating pulses of ultrasonic energy for use with an ophthalmic surgical device. | 12-30-2010 |
| 20100324581 | Torsional Ultrasound Hand Piece That Eliminates Chatter - A torsional ultrasound surgical hand piece lessens or eliminates chatter from lens material by imparting a twisting, rotary motion to a tip of a phacoemulsification needle at a resonant frequency in excess of 32 kHz. The hand piece has a horn that is designed to operate at an elevated frequency while maintaining size constraints for hand-held ophthalmic instruments. Optionally, heat generation is reduced either through the use of a polyimide tubing situated between the needle and the infusion sleeve, through the use of thermal watch to prevent overheating at the incision, and/or through the use of a bypass hole in the needle that diverts flow under suction into the needle via the bypass hole instead of exiting through an irrigation opening in the infusion sleeve when a tip port is occluded by lens material. | 12-23-2010 |
| 20100311716 | USE OF INHIBITORS OF JUN N-TERMINAL KINASES TO TREAT GLAUCOMA - Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection. | 12-09-2010 |
| 20100280089 | USE OF INHIBITORS OF JUN N-TERMINAL KINASES FOR THE TREATMENT OF GLAUCOMATOUS RETINOPATHY AND OCULAR DISEASES - Compositions and methods for the treatment of glaucoma and other ocular diseases are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK), such as SP600125 in the treatment of glaucoma and other ocular diseases. | 11-04-2010 |
| 20100268388 | Method of Controlling A Surgical System Based on Irrigation Flow - A surgical system that is able to sense the onset of an occlusion or other surgical event as well as the instant an occlusion breaks. To help avoid overheating of the tip, the system determines a temperature of an eye using irrigation flow rate and reduces the power to the handpiece automatically if an overheating situation is predicted. Alternatively or in addition, the system monitors the power drawn by the handpiece, which is indicative of the cutting load on the tip, and automatically adjusts the power or stroke of the tip to compensate for increased loads on the tip. | 10-21-2010 |
| 20100267664 | OPHTHALMIC COMPOSITIONS CONTAINING POLYSACCHARIDE-BORATE GELLING SYSTEM - Topical ophthalmic compositions that form a gel or partial gel upon application to the eye are described. The compositions are particularly useful as artificial tears and ocular lubricants, but may also be utilized for the topical delivery of pharmaceutically active compounds to the eye. The compositions contain a polysaccharide/borate gelling system. The polysaccharides that may be utilized contain cis-diol groups and have a structure that is predominately linear, with a slight degree of branching. | 10-21-2010 |
| 20100249134 | Use of Beta-Adrenoceptor Antagonists for the Manufacture of a Medicament for the Treatment of Disorders of the Outer Retina - Compositions and methods for treating disorders of the outer retina with β-adrenoceptor antagonists are disclosed. | 09-30-2010 |
| 20100216777 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS - Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed. | 08-26-2010 |
| 20100204244 | AGENTS FOR TREATMENT OF DIABETIC RETINOPATHY AND DRUSEN FORMATION IN MACULAR DEGENERATION - Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid other than genistein, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof. | 08-12-2010 |
| 20100204194 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES - The use of SOD mimics particularly pentaazacycle Mn | 08-12-2010 |
| 20100204086 | BONE MORPHOGENIC PROTEINS (BMP), BMP RECEPTORS AND BMP BINDING PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF GLAUCOMA - The present invention provides methods and kits for diagnosing and treating glaucoma. | 08-12-2010 |
| 20100179117 | SUPEROXIDE DISMUTASE MIMICS FOR THE TREATMENT OF OCULAR DISORDERS AND DISEASES - The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed. | 07-15-2010 |
| 20100173852 | USE OF AGENTS THAT DOWN-REGULATE EXPRESSION OF TANIS AND/OR P21 Waf1/Cip1/Sd1 GENES, AND USE OF AGENTS THAT INHIBIT, DEGRADE, SEQUESTER OR PREVENT THE NEUROTOXICITY OF GENE PRODUCT PROTEINS OF TANIS AND P21 Waf1/Cip1/Sd1 GENES - The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21 | 07-08-2010 |
| 20100168438 | DUAL FUNCTION UV-ABSORBERS FOR OPHTHALMIC LENS MATERIALS - Disclosed are UV absorbers that contain a labile functional group capable of initiating free radical polymerization. | 07-01-2010 |
| 20100168121 | COMPOUNDS WITH 5-HT1A ACTIVITY USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA - Compositions and methods for treating disorders of the outer retina with compounds with 5-HT | 07-01-2010 |
| 20100168116 | 3,6-SUBSTITUTED IMIDAZOL[1,2-B]PYRIDAZINE ANALOGS FOR TREATING ALLERGIC AND INFLAMMATORY DISEASES - Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound. | 07-01-2010 |
| 20100152279 | RNAi Inhibition of Serum Amyloid A For Treatment of Glaucoma - RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression. | 06-17-2010 |
| 20100113641 | UV/VISIBLE LIGHT ABSORBERS FOR OPHTHALMIC LENS MATERIALS - Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials. | 05-06-2010 |
| 20100099771 | USE OF COOLING AGENTS TO RELIEVE MILD OCULAR IRRITATION AND ENHANCE COMFORT - Ophthalmic compositions containing very low concentrations (e.g., 1 to 50 ppm) of cooling agents are described. The cooling agents are less volatile and less prone to causing ocular discomfort than agents previously utilized to obtain an ocular cooling effect, such as menthol. The cooling agents are preferably contained in a vehicle that forms a gel or partial gel upon application to the eye. | 04-22-2010 |
| 20100063052 | USE OF SERUM AMYLOID A GENE IN DIAGNOSIS AND TREATMENT OF GLAUCOMA AND IDENTIFICATION OF ANTI-GLAUCOMA AGENTS - The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A. | 03-11-2010 |
| 20100048608 | Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases - Ophthalmic compositions containing HDAC inhibitors and their use for treating ocular neovascular or edematous diseases and disorders are disclosed. | 02-25-2010 |
| 20100048522 | Method Of Treating Otic Infections With Moxifloxacin Compositions - Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. | 02-25-2010 |
| 20100036406 | Method of Controlling a Surgical System Based on a Load on the Cutting Tip of a Handpiece - A surgical system that is able to sense the onset of an occlusion or other surgical event as well as the instant an occlusion breaks. To help avoid overheating of the tip, the system determines an approximate temperature of the eye using an irrigation flow rate and reduces the power to the handpiece automatically if an overheating situation is predicted. Alternatively or in addition, the system monitors the power drawn by the handpiece, which is indicative of the cutting load on the tip, and automatically adjusts the power or stroke of the tip to compensate for increased loads on the tip. | 02-11-2010 |
| 20100035969 | RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERS - RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention. | 02-11-2010 |
| 20100012889 | UV-ABSORBERS FOR OPHTHALMIC LENS MATERIALS - Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed. | 01-21-2010 |
| 20090312390 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) FOR TREATING GLAUCOMA - The use of inhibitors of GSK-3 useful for treating glaucoma is disclosed. | 12-17-2009 |
| 20090281209 | HIGH REFRACTIVE INDEX OPHTHALMIC DEVICE MATERIALS - High refractive index copolymers suitable for use in ophthalmic devices are disclosed. The copolymers comprise a single aryl hydrophobic monomer as a device forming monomer. In addition, the copolymers comprise a non-polymerizable block copolymer surfactant. The copolymers have a reduced tendency to form glistenings when stored in water at physiological temperatures. | 11-12-2009 |
| 20090258955 | INTRAOCULAR IRRIGATING SOLUTION HAVING IMPROVED FLOW CHARACTERISTICS - Improved intraocular irrigating solutions are described comprising a cellulose derivative such as hydroxypropylmethylcellulose. In addition, certain solutions of the present invention comprise glutathione and dextrose. The solutions have enhanced viscosities that reduce the risk of damage to intraocular tissues during intraocular surgical procedures by reducing the turbulence of the solutions and dampening the movement of tissue fragments and air bubbles. The solutions preferably also have modified surface tensions that more closely resemble the surface tension of the aqueous humor. | 10-15-2009 |
| 20090215735 | TOPICAL SOLUTION FORMULATIONS CONTAINING A CORTICOSTEROID AND A CYCLODEXTRIN - Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose. | 08-27-2009 |
| 20090203614 | USE OF AGENTS THAT PREVENT THE GENERATION OF AMYLOID-LIKE PROTEINS AND/OR DRUSEN, AND/OR USE OF AGENTS THAT PROMOTE SEQUESTRATION AND/OR DEGRADATION OF, AND/OR PREVENT THE NEUROTOXIC EFFECTS OF SUCH PROTEINS IN THE TREATMENT OF MACULAR DEGENERATION - The present invention provides compositions and methods for treating age-related macular degeneration (AMD). More specifically, the methods of the invention target amyloid proteins and drusen that tend to accumulate in the eyes of those patients suffering from AMD. AMD is treated in the methods of the invention by providing agents that sequester and/or degrade such amyloid deposits and/or drusen such that a patient's vision is improved or restored. | 08-13-2009 |
| 20090156693 | OPHTHALMIC COMPOSITIONS CONTAINING POLYSACCHARIDE/BORATE GELLING SYSTEM - Topical ophthalmic compositions that form a gel or partial gel upon application to the eye are described. The compositions are particularly useful as artificial tears and ocular lubricants, but may also be utilized for the topical delivery of pharmaceutically active compounds to the eye. The compositions contain a polysaccharide/borate gelling system. The polysaccharides that may be utilized contain cis-diol groups and have a structure that is predominately linear, with a slight degree of branching. | 06-18-2009 |
| 20090156566 | METHOD OF TREATING MIDDLE EAR INFECTIONS - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane. | 06-18-2009 |
| 20090149659 | 1-ALKYL-3-AMINOINDAZOLES - Methods of making 1-alkylindazoles are described. The methods involve reacting a 2-alkylaminobenzonitrile with a nitrosating agent followed by reduction-cyclization of the resulting nitrosamine to form a 1-alkyl-3-aminoindazole. The 1-alkyl-3-aminoindazole can be deaminated to form a 1-alkylindazole which ultimately can be used to form desired indazoles which are preferably pharmaceutically active products. The process of the present invention further permits the formation of enantiomerically enriched or pure indazoles such as aminoalkyl indazoles. | 06-11-2009 |
| 20090132039 | LOW-TACK OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS - Disclosed are soft, high refractive index, acrylic materials. These materials, especially useful as intraocular lens materials, contain one or more aryl acrylic hydrophobic monomers as principal device-forming monomers and a tack-reducing macromer additive. In addition to their use as intraocular lens materials, the present materials are also suitable for use in other ophthalmic or otorhinolaryngological devices, such as contact lenses, keratoprostheses, corneal inlays or rings; otological ventilation tubes and nasal implants. | 05-21-2009 |
| 20090124960 | Monitoring Thermal Conditions To Vary Operation of an Ultrasonic Needle Tip of a Surgical Instrument - A method and apparatus to operate a surgical instrument in response to a thermal condition being detected that warrants curtailment of further operation. When the thermal condition is reached, command signals are generated that cause a needle of the surgical instrument to either have its vibrational speed slowed, have its vibrational movement stopped, or have it withdrawn from its relative position. The detection is of infrared radiation wavelengths and is carried out with either a thermal imaging device of a thermal recognition device. A corresponding temperature of the detected infrared radiation wavelengths is compared to a critical temperature to determine whether the thermal condition has been reached. | 05-14-2009 |
| 20090093604 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS - Disclosed are soft, high refractive index, acrylic device materials. The materials contain a hydrophilic side-chain macromer for glistening resistance. | 04-09-2009 |
| 20090093603 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS - Disclosed are soft, high refractive index, acrylic device materials. The materials comprise di-block or tri-block macromers containing a hydrophilic block in the polymer backbone. The materials have improved glistening resistance. | 04-09-2009 |
| 20090093592 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS - Disclosed are soft, high refractive index, acrylic device materials. The materials comprise di-block or tri-block macromers containing hydrophilic side-chains. The materials have improved glistening resistance. | 04-09-2009 |
| 20090088544 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS CONTAINING AN ALKYL ETHOXYLATE - Disclosed are soft, high refractive index, acrylic device materials. The materials contain a functionalized alkyl ethoxylate to reduce glistenings. | 04-02-2009 |
| 20090088493 | OPHTHALMIC AND OTORHINOLARYNGOLOGICAL DEVICE MATERIALS CONTAINING AN ALKYLPHENOL ETHOXYLATE - Disclosed are soft, high refractive index, acrylic device materials. The materials contain a functionalized alkylphenol ethoxylate to reduce glistenings. | 04-02-2009 |
| 20090048146 | USE OF AGENTS THAT UPREGULATE CRYSTALLIN EXPRESSION IN THE RETINA AND OPTIC NERVE HEAD - The present invention relates to methods to treat and/or prevent optic nerve damage in a subject by administering a composition comprising a crystallin agonist. | 02-19-2009 |
| 20090043105 | OPHTHALMIC LENS MATERIALS CONTAINING CHROMOPHORES THAT ABSORB BOTH UV AND SHORT WAVELENGTH VISIBLE LIGHT - Chromophores that absorb both UV and short wavelength visible light are disclosed. The chromophores are particularly suitable for use in intraocular lens materials. | 02-12-2009 |
| 20090043007 | OPHTHALMIC LENS MATERIALS CONTAINING CHROMOPHORES THAT ABSORB BOTH UV AND SHORT WAVELENGTH VISIBLE LIGHT - Chromophores that absorb both UV and short wavelength visible light are disclosed. The chromophores are particularly suitable for use in intraocular lens materials. | 02-12-2009 |
| 20090043006 | High Refractive Index Ophthalmic Device Materials - High refractive index copolymers suitable for use in ophthalmic devices are disclosed. The copolymers comprise two or more aryl hydrophobic monomers and a non-polymerizable propylene oxide-ethylene oxide-propylene oxide block copolymer surfactant having a molecular weight of approximately 3600 and approximately 40% ethylene oxide units by weight. The copolymers have a reduced tendency to form glistenings when stored in water at physiological temperatures compared to similar copolymers lacking the non-polymerizable surfactant. | 02-12-2009 |
| 20090036371 | Use of Serum Amyloid A Gene in Diagnosis and Treatment of Glaucoma and Identification of Anti-Glaucoma Agents - The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A. | 02-05-2009 |
| 20090030085 | USE OF BIS-AMINES TO ENHANCE THE ANTIMICROBIAL ACTIVITY OF AQUEOUS COMPOSITIONS - The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses. | 01-29-2009 |
| 20090023835 | High Ion And Metabolite Flux Lenses And Materials - An exemplary embodiment provides a biocompatible polymer composition suitable for making intraocular lenses, especially posterior chamber phakic lenses, that includes a hydrogel having an equilibrium water content of less than about 55 wt. %. The hydrogel has a refractive index greater than about 1.41 and a sodium ion flux between about 16 to about 20 μeq-mm/hr/cm | 01-22-2009 |
| 20090018651 | OFF-AXIS ANTI-REFLECTIVE INTRAOCULAR LENSES - Exemplary embodiments provide a coated intraocular lens that has a lens body with a first refractive index and an anti-reflective coating. The coating covers at least a portion of the lens body and has a second index of refraction that is less than the first index of refraction of the lens body. The anti-reflective coating reduces the intensity of reflections produced from off axis light incident on the lens body by at least a factor of 2.5 times and enhancing light transmission. | 01-15-2009 |
| 20090012291 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA - Substituted furo[2,3-g]indazoles for lowering intraocular pressure and treating glaucoma are disclosed. | 01-08-2009 |
| 20080269891 | INTRAOCULAR LENS WITH EDGE MODIFICATION - Intraocular lenses (IOLs) with modified edge characteristics are disclosed to inhibit transverse propagation of internally reflected light rays in order to alleviate, and preferably eliminate, dysphotopsia and/or the perception of dark shadows reported by some users. In one embodiment, IOL designs are disclosed that incorporate an opaque edge or other mechanisms for capturing internally reflected peripheral light rays. In other embodiments, the peripheral region can include a light scattering material or can have a disproportional thickness or be contoured to redirect peripheral rays. | 10-30-2008 |
| 20080269884 | GRADUATED BLUE FILTERING INTRAOCULAR LENS - Devices and methods utilizing novel intraocular lens (IOL) designs are discussed herein. One aspect relates to IOLs having an optic with non-uniform light transmissivity. For example, the optic of the IOL can include a central region having a reduced light transmissivity relative to another portion of the optic. In addition, or alternatively, the optic can have a peripheral region having reduced light transmissivity. Such IOLs can potentially be utilized to alter the light distribution impinging on a subject's retina, which can be tailored to specific lighting situations such as bright and dim light conditions. Such IOLs can also, or alternatively, be used to help alleviate the perception of dark shadows known as negative dysphotopsia. Other aspects and features of IOLs, and methods, are also discussed. | 10-30-2008 |
| 20080269883 | OCULAR IMPLANT TO CORRECT DYSPHOTOPSIA, GLARE, HALOS AND DARK SHADOW TYPE PHENOMENA - Methods and devices for inhibiting the dark shadow effect, known as dysphotopsia, perceived by some subjects having implanted intraocular lenses (IOLs) are presented. In one aspect, an IOL can include an optic and one or more fixation members for facilitating placement of the IOL. The fixation member can be adapted to position the optic sufficiently close to the iris to inhibit dysphotopsia. As some examples, a fixation member can position an optic to within some distance of the tip of the iris, or the fixation member can be adapted to contact a portion of an eye posterior to an optic's posterior surface; or the fixation member can have an end that is posterior to a posterior surface of the optic. Various techniques for achieving these improvements among others are discussed, both in terms of the structures of improved IOLs, and methods for alleviating dysphotopsia. | 10-30-2008 |
| 20080269249 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS - Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed. | 10-30-2008 |
| 20080241224 | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions For Intraocular Use - Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient. | 10-02-2008 |
| 20080221675 | Dual Function UV-Absorbers for Ophthalmic Lens Materials - Disclosed are UV absorbers that contain a labile functional group capable of initiating free radical polymerization. | 09-11-2008 |
| 20080218863 | Color Compensating Retinal Safety Filter - A filter and method for filtering an optical beam are disclosed. One embodiment of the filter is an optical filter for filtering an incident light beam, comprising an optically effective material characterized by: a light transmittance of less than 1% for wavelengths below 420 nm; and a light transmittance for wavelengths complementary and near complementary to wavelengths below 420 nm that, combined with the transmittance for wavelengths below 420 nm, will yield a filtered light beam having a luminosity of about 90% and an excitation purity of 5% or less. The complementary wavelengths can be wavelengths above about 640 nm, wavelengths above about 660 nm, and/or wavelengths from about 540 nm to about 560 nm. Further, in one embodiment the difference between the light transmittance just below 420 nm and the light transmittance just above 420 nm can be greater than 90%. Above 420 nm, in some embodiments, the light transmittance can be arbitrarily determined. The optically effective material can be optical-grade glass, an optical-grade plastic or polymer, a thin-film dielectric coating, or an optical-grade glass or plastic coated with a dielectric coating. The optical filter can be mounted downstream of an illumination source exit aperture, wherein the illumination source produces the incident light beam, and upstream of a site to be illuminated by the filtered light beam. Alternatively, the optical filter can be operably mounted on a set of viewing optics of a surgical microscope to filter a reflected portion of a light beam produced by an illumination source and used to illuminate a site, such as a surgical site. | 09-11-2008 |
| 20080214513 | METHOD OF TREATING MIDDLE EAR INFECTIONS - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane. | 09-04-2008 |
| 20080208334 | COATED MEDICAL IMPLANTS AND LENSES - Coated medical implants have an implant body configured for securing in or adjacent to body tissue of a patient. The implant body has an implant surface and a coating is formed on at least a portion of the implant surface. The coating includes a coating outer surface of a first chemical component that is chemically bonded to a carboxylate functionality of a second chemical component. The second chemical component is immobilized by amide linkage to an underlying third chemical component that is plasma coated directly onto implant body surfaces. The coating either inhibits or prevents the adhesion of protein and/or cellular proliferation or may be a non-fouling coating. | 08-28-2008 |
